MADRIGAL PHARMACEUTICALS INC

About

Madrigal Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH). The company’s lead product candidate is a selective thyroid hormone receptor-beta agonist designed to address the underlying pathology of liver disease. Madrigal operates within the competitive pharmaceutical preparations sector, aiming to provide treatment options for a condition with significant unmet medical needs.